Novo makes bombshell $6.5B counteroffer to Pfizer's acquisition of obesity biotech Metsera

Eli Lilly withdraws phase 2b trial of $1.9B obesity bet before starting enrollment

https://www.businesswire.com/news/home/20250922965053/en/Pfizer-to-Acquire-Metsera-and-its-Next-Generation-Obesity-Portfolio

Pfizer inks $4.9B upfront Metsera buyout to beef up obesity pipeline following internal setbacks

Novo Nordisk looks to next generation of obesity, diabetes drugs with $550M Replicate research deal

Eli Lilly shares drop after obesity pill shows modest late-stage trial results

Novo Nordisk names new CEO as the obesity drugmaker cuts sales, profit outlook

Eli Lilly enlists Camurus to help unlock long-acting obesity market in deal worth up to $870M

Viking Rises as Pfizer’s Oral Obesity Med Falters

Pfizer axes oral GLP-1 asset over liver injury, blowing hole in obesity plan

BioAge Drops Lead Obesity Asset Months After IPO

Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results

Amgen’s monthly obesity drug matches competition in phase 2, but investors are unimpressed

Pfizer, Flagship Pioneering to Target Obesity Treatments Under 2023 Partnership | BioSpace

With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments

Novo Nordisk Jumps On Strong Results For New Obesity Drug

Association of accelerometer-measured physical activity and its change with progression to chronic kidney disease in adults with type 2 diabetes and overweight/obesity - PubMed

Novo Deepens Obesity, MASH Expertise in Deals Worth $1B with Two Flagship Biotechs | BioSpace